SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (365)1/20/2016 4:18:41 PM
From: scaram(o)uche   of 684
 
Share distribution from Kearny Venture partners.

Timing is interesting. Are all of the assignees governed by the same selling rules before a secondary that apply to the fund? Assume the answer is yes......

archive.fast-edgar.com

On January 12, 2016, in connection with a secondary sale of the Issuer’s Common Stock to the public, each of KVP and KVPE acquired from the Issuer an aggregate of 444,444 shares of the Issuer’s Common Stock for a purchase price of $9.00 per share, or an aggregate of $4,000,000.



The source of the funds for all purchases by the Reporting Persons was from working capital.



ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.



Items 5(a) and 5(b) of the Original Schedule 13D are hereby amended and restated in their entirety as follows:



(a,b) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row 10 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon 37,881,738 shares of Common Stock outstanding as of January 12, 2016.



Item 5(c) of the Original Schedule 13D is hereby amended and restated in its entirety as follows:



(c) In addition to the purchases set forth in Item 3 above, the Reporting Persons effected the following transaction in the Issuer’s Common Stock during the past 60 days:



On January 8, 2016, TWHVP distributed an aggregate of 444,704 shares of the Issuer’s Common Stock to its respective partners, members and assignees in a pro-rata, in-kind distribution.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext